Your session is about to expire
← Back to Search
IcoSema for Type 2 Diabetes
Study Summary
This trial will compare a new once-weekly combination insulin to daily insulin in people with type 2 diabetes, to see how well it controls blood sugar levels.
- Type 2 Diabetes
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have severe chronic heart failure that is classified as Class IV by doctors.You have experienced frequent and severe low blood sugar episodes in the past year.You have had pancreatitis (an inflammation of the pancreas) within the past 180 days before the screening.
- Group 1: IcoSema
- Group 2: Insuling glargine/insulin aspart
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many human subjects are included in this experiment?
"Correct, the clinical trial is still recruiting patients. 39 sites across the nation are looking for a total of 680 participants. The study was originally posted on 11/30/2021 and last updated on 11/7/2022 according to clinicaltrials.gov"
For what conditions is IcoSema regularly prescribed?
"IcoSema can be used to manage hyperglycemia, type 2 diabetes mellitus, and help patients get active through exercise."
Is IcoSema likely to lead to any adverse health effects?
"IcoSema's safety is estimated to be a 3. This rating comes from the fact that it is a Phase 3 trial, which suggests that not only does some data support efficacy, but multiple rounds of data support safety."
Are the results of IcoSema backed by other scientific research?
"Currently, there are 29 different clinical trials evaluating the efficacy of IcoSema. Of these active studies, 7 have progressed to Phase 3 testing. The majority of these trials taking place in Baltimore, MD; however, 477 locations across the world are running similar investigations."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Novo Nordisk Investigational Site: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger